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RESUMO – O diagnóstico clínico de dermatomiosite é muitas vezes difícil e desafiante. A presença de uma história clínica clás-
sica, aliada a um exame físico completo e ao uso dos anticorpos específicos para miosite recentemente descritos, pode levar ao 
diagnóstico mais precoce desta entidade. Desta forma e com o início atempado da terapêutica, minimiza-se o risco de progressão 
da doença.
Apresentamos o caso de uma doente com mãos-de-mecânico e uma história prévia de toxidermia à hidroxicloroquina. Embora 
estes achados não sejam patognomónicos de dermatomiosite, quando associados a uma história clínica e exame físico típicos, são 
ferramentas diagnósticas úteis.
PALAVRAS-CHAVE – Anticorpos; Dermatoses da Mão; Dermatomiosite; Enzimas Ativadoras de Ubiquitina; Erupção por Medi-
camentos; Hidroxicloroquina/efeitos adversos.
Mechanic´s Hands and Drug Eruption to 
Hydroxychloroquine: Precious Diagnostic Tools  
ABSTRACT – The clinical diagnosis of dermatomyositis can be difficult and challenging. In the right clinical setting and with the 
use of the recently described myositis specific antibodies, an earlier diagnosis can be made and therapeutic approaches promptly 
started, minimizing the risk of disease progression.
We herein present a case of a patient with mechanic’s hands and a previously documented drug eruption to hydroxychloroquine. 
Although these clinical findings are not pathognomonic of dermatomyositis, in the right clinical scenario, they are precious diag-
nostic tools. 
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tin-Activating Enzymes.
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INTRODUCTION
Dermatomyositis (DM) is a rare idiopathic inflammatory 
myopathy with diverse cutaneous and systemic manifesta-
tions.1 It can occur at any age, having a bimodal distribu-
tion – between 5 and 15 years old in the juvenile form and 
between 40 and 60 years old in the adult form –, and a 
higher prevalence in the female gender with a 2:1 female/
male ratio.2
In the absence of the classical cutaneous findings and sys-
temic symptoms, the diagnosis of DM can be challenging. Ne-
vertheless, the use of the recently described myositis specific 
antibodies (MSAs) can aid in establishing an earlier diagnosis, 
promptly starting treatment and minimizing the risk of disease 
progression.3,4 Although the role of MSAs in the pathogenesis 
of DM remains to be completely determined, it is envisaged 
that these antibodies will aid in the subclassification of DM 
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into homogenous clinical phenotypes and in the guidance of 
the treatment.3,4 It is known that pathophysiologic differences 
exist between autoantibody subsets in DM, leading to different 
clinicoserologic phenotypes, with variable prognosis and dis-
tinctive responses to treatment.4-6
Adverse skin reactions to hydroxychloroquine (HCQ), a 
standard first-line treatment in DM, have been reported and a 
strong association with anti-small ubiquitin-like modifier acti-
vating enzyme (SAE-1/2) antibodies was recently described.7
CASE REPORT
A 70-year-old caucasian woman presented with a three-
-month history of a skin rash, mainly affecting sun-exposed 
areas, and low-grade fever. She denied any difficulty combing 
hair, getting out of a seated position or swallowing, as well 
as changes in voice, cough, shortness of breath, or dyspnea 
on exertion. She recalled a previous diagnosis of cutaneous 
lupus erythematosus (LE) made at another healthcare facility 
five years before. At that time, a trial of HCQ was initiated 
but soon interrupted due to a serious drug reaction, charac-
terized by a generalized maculopapular blanching skin rash 
with palmoplantar and mucosal involvement. Recent treatment 
with methotrexate (maximum dose of 10 mg weekly, due to 
gastrointestinal intolerance) was ineffective after three months.
On physical examination, heliotrope and a photodistri-
buted scaly erythematous rash of the upper trunk and limbs 
were present with a V distribution on the anterior chest (V 
sign), and the shawl, sleeve, and holster signs. Gottron´s 
papules and Gottron´s sign of the extension surface of the 
metacarpophalangeal and proximal interphalangeal joints 
of the hands, elbows, and knees, were also documented. 
The dorsal (Fig. 1A) and lateral (Fig. 1B) aspects of the 
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Figure 1 - Cutaneous findings on the hands at the time of diagnosis. (A) – Erythematous, hyperkeratotic and slightly scaly papules – Gottron´s 
papules – and plaques on the dorsum of the digits with ragged cuticle/cuticular hypertrophy and periungual erythema. (B) – Hyperkeratotic, scaly and 





fingers were hyperkeratotic, scaly, and fissured – mechanic’s 
hands –, with ragged cuticle and periungual erythema. The 
remaining physical examination, namely the cardiopulmo-
nary auscultation and neurologic exam, was unremarkable.
Laboratory examination revealed low titer antinuclear 
antibodies positivity (1/80) and a strong positivity for anti-
-SAE-1/2 antibodies was documented by immunoblotting 
(Euroline® Autoimmune Inflammatory Myopathies 16Ag). 
Anti-dsDNA, anti-Ro52/60, anti-La, anti-Sm, anti-RNP-
-Sm, anti-Scl-70, anti-PM-Scl-75/100, anti-Ku, anti-SRP, 
anti-NXP2, anti-MDA5, anti-TIF1g, anti-Mi-2a/b, and an-
tisynthetase (anti-Jo-1, anti-OJ, anti-EJ, and anti-PL-7/12) 
antibodies were negative. A skin biopsy revealed an inter-
face dermatitis with basal cell vacuolization, apoptotic ke-
ratinocytes, and perivascular lymphocytic infiltrate. There 
was no evidence of muscle involvement (serum creatinine 
kinase, myoglobin and aldolase levels within the normal 
range and electromyogram without changes), interstitial 
lung disease (normal chest computed tomography and 
lung function testing) or underlying solid or hematolo-
gic malignancy. As such, a diagnosis of amyopathic DM 
was made. The Cutaneous DM Disease Area and Severity 
Index (CDASI) total activity score (range 0-100) at the time 
of diagnosis was 40 (moderate to severe disease).8
The patient was initially treated with medium to high-
-dose systemic glucocorticoids (SGC; up to 0.5 mg/kg 
daily, 40 mg of prednisolone), azathioprine (up to 1 mg/
kg daily, 75 mg), topical betamethasone ointment (0.5 
mg/g twice daily) and strict photoprotection with the use 
of broad-spectrum sunscreen (sun protective factor of at 
least 50). Treatment with high-dose SGC induced diabe-
tes mellitus, so the dose was tapered to 20 mg daily, and 
azathioprine had to be stopped two months later due to 
hematologic and hepatic toxicity. At this point and with 
disease relapse, mycophenolate mofetil (2000 mg daily) 
was started, initially associated with intravenous immu-
noglobulin (IVIG; 2 mg/kg monthly). After a 12-month 
period under the aforementioned treatment, the patient 
persisted with moderately active disease (Fig. 2), CDASI of 
22, and corticodependency (worsening of the skin lesions 
with less than 10 mg of prednisolone). Only after the asso-
ciation of intravenous rituximab (RTX; 2 g six-monthly) with 
mycophenolate mofetil a complete disease remission and 
gradual weaning of prednisolone were accomplished after 
the first cycle of RTX. One year later, the patient persists 
in clinical remission and without new symptoms or serious 
side effects from the current treatment.
DISCUSSION
Although the diagnosis of DM could be challenging, a 
physical examination alone usually leads expert clinicians 
to its suspicion and a correct diagnosis.9 In all cases, es-
pecially when the skin findings are not straightforward, 
a thorough and detailed skin examination is mandatory. 
Although not considered to be pathognomonic of DM, 
mechanic’s hands are a precious diagnostic tool, enabling 
a correct and prompt differential diagnosis.4 Classically 
described in patients with the antisynthetase syndrome, 
they can be found in patients with DM associated with 
other MSAs and with other autoimmune diseases like LE.4,6 
Actually, before the correct diagnosis of amyopathic DM, 
our patient had a previous clinical diagnosis of LE, which 
illustrates the difficulty in distinguishing between these two 
entities. In addition to the presence of mechanic’s hands, 
this patient presented other clinical findings that led to 
a probable diagnosis of DM, before complementary stu-
dies – the existence of other typical cutaneous lesions and 
a history of previously documented adverse skin reaction 
to HCQ. Regarding this latter aspect, adverse skin reac-
tions to HCQ have been previously reported as common 
in patients with DM, particularly when associated with an-
ti-SAE-1/2 antibodies – approximately 4-fold increase in 
risk compared to those without this antibody.7
In DM it is important to timely install appropriate 
treatment and most patients do not respond to isolated 
skin directed therapies and will require systemic thera-
pies.9 Antimalarials have been the preferred initial treat-
ment for cutaneous DM due to their photoprotective and 
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Figure 2 - Cutaneous findings on the face and trunk before treat-
ment with rituximab: periorbital edema with violaceous erythema of the 
face – heliotrope rash – and of the anterior upper chest – V sign.  
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anti-inflammatory mechanisms.9 In this patient, the rein-
troduction of HCQ was not considered to be a reasonable 
option, according to the clinical aspects of the drug erup-
tion and immune profile, although cases of HCQ rechal-
lenge are well documented in the literature, particularly 
in those with previous mild drug eruptions.10 SGC and 
IVIG are sometimes used for severe and refractory cuta-
neous DM, as a transition therapy until the effect of other 
systemic immunosuppressant drugs is documented.9,11 In 
the absence of high-quality evidence for the use of im-
munosuppressive therapy, the choice of the primary agent 
depends on the personal physician’s experience and the 
patient’s comorbidities and co-medication.9,11 If the disea-
se is refractory to standard immunosuppression and IVIG, 
treatment escalation to RTX or cyclophosphamide can be 
considered, as in the presented case. Although there are 
a lack and conflicting results supporting the use of RTX 
for cutaneous disease, a large prospective, randomized 
controlled trial (RIM trial) revealed a beneficial effect, in a 
post hoc analysis.12
Overall this case highlights the importance of non-clas-
sical clinical findings, namely mechanic’s hands and a his-
tory of drug eruption to HCQ, for the diagnosis of DM, 
while providing insights regarding subclassification accor-
ding to the associated MSAs and treatment in refractory 
cases.
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